These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 34772581

  • 1. Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin.
    Yip PL, Mok KCJ, Ho HS, Lee WYV, Wong ACL, Lau CT, Wong FCS, Yeung KW, Lee SF.
    Clin Oncol (R Coll Radiol); 2022 Apr; 34(4):e160-e167. PubMed ID: 34772581
    [Abstract] [Full Text] [Related]

  • 2. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.
    Chen WC, Jackson A, Budnick AS, Pfister DG, Kraus DH, Hunt MA, Stambuk H, Levegrun S, Wolden SL.
    Cancer; 2006 Feb 15; 106(4):820-9. PubMed ID: 16421885
    [Abstract] [Full Text] [Related]

  • 3. Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Zhu W, Chen F, Li J, Wang W, Zhang H, Yang G, Zou L, Zhu Y, Yuan W, Ding H, Song X, Wang S.
    Acta Otolaryngol; 2019 Mar 15; 139(3):263-268. PubMed ID: 30870056
    [Abstract] [Full Text] [Related]

  • 4. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
    Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, Lee AW, Chow SK.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1335-42. PubMed ID: 18922648
    [Abstract] [Full Text] [Related]

  • 5. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients.
    Petsuksiri J, Sermsree A, Thephamongkhol K, Keskool P, Thongyai K, Chansilpa Y, Pattaranutaporn P.
    Radiat Oncol; 2011 Feb 20; 6():19. PubMed ID: 21333025
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and chemoradiotherapy.
    Wei Y, Zhou T, Zhu J, Zhang Y, Sun M, Ding X, Wang D, Li H, Li B.
    Cell Biochem Biophys; 2014 Jul 20; 69(3):433-7. PubMed ID: 24510513
    [Abstract] [Full Text] [Related]

  • 7. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
    Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, Am Zehnhoff-Dinnesen A, Eich HT.
    Strahlenther Onkol; 2017 Nov 20; 193(11):910-920. PubMed ID: 28887665
    [Abstract] [Full Text] [Related]

  • 8. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment.
    Kwong DL, Wei WI, Sham JS, Ho WK, Yuen PW, Chua DT, Au DK, Wu PM, Choy DT.
    Int J Radiat Oncol Biol Phys; 1996 Sep 01; 36(2):281-9. PubMed ID: 8892450
    [Abstract] [Full Text] [Related]

  • 9. Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy.
    Ho JCS, Ma BBY, Chow JCH.
    Cancers (Basel); 2024 Sep 23; 16(18):. PubMed ID: 39335208
    [Abstract] [Full Text] [Related]

  • 10. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):779-88. PubMed ID: 18707819
    [Abstract] [Full Text] [Related]

  • 11. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma.
    Oh YT, Kim CH, Choi JH, Kang SH, Chun M.
    Radiother Oncol; 2004 Jul 01; 72(1):79-82. PubMed ID: 15236878
    [Abstract] [Full Text] [Related]

  • 12. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
    Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY.
    J Clin Oncol; 2006 Apr 20; 24(12):1904-9. PubMed ID: 16622266
    [Abstract] [Full Text] [Related]

  • 13. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Das N, Kaushal D, Patro SK, Pareek P, Dixit A, Soni K, Prakasan Nair N, Choudhury B, Goyal A.
    Acta Otolaryngol; 2021 Sep 20; 141(9):885-893. PubMed ID: 34486907
    [Abstract] [Full Text] [Related]

  • 14. Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma.
    Wu L, Chung YL.
    Int J Radiat Oncol Biol Phys; 2019 May 01; 104(1):165-176. PubMed ID: 30654091
    [Abstract] [Full Text] [Related]

  • 15. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
    Mahdavi SR, Rezaeyan A, Nikoofar A, Bakhshandeh M, Farahani S, Cheraghi S.
    J Cancer Res Ther; 2020 May 01; 16(3):539-545. PubMed ID: 32719264
    [Abstract] [Full Text] [Related]

  • 16. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.
    Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M, Khoie S, Gharehbagh EJ, Farahani S, Mohebbi A, Vasheghani M, Zare M, Nikoofar A, Mahdavi SR.
    Med Oncol; 2015 Jul 01; 32(7):200. PubMed ID: 26071124
    [Abstract] [Full Text] [Related]

  • 17. Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region.
    Yücel B, Erdiş E, Bahar S, Akkaş Atasever E, Celasun MG, Altuntaş EE.
    Turk Arch Otorhinolaryngol; 2022 Dec 01; 60(4):212-219. PubMed ID: 37456600
    [Abstract] [Full Text] [Related]

  • 18. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population.
    Chan SL, Ng LS, Goh X, Siow CH, Goh HL, Goh BC, Cheo T, Loh KS, Brunham LR.
    Head Neck; 2018 Jul 01; 40(7):1425-1433. PubMed ID: 29451951
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ, Mo HY, Luo DH, Hu WH, Jin T.
    Oral Oncol; 2018 Oct 01; 85():95-100. PubMed ID: 30220326
    [Abstract] [Full Text] [Related]

  • 20. Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials.
    Du CR, Ying HM, Kong FF, Zhai RP, Hu CS.
    Radiat Oncol; 2015 Mar 26; 10():70. PubMed ID: 25889937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.